Trial Profile
Safety of lenalidomide as maintenance therapy after allogeneic hematopoietic stem cell transplantation for multiple myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Apr 2020
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms E-FLAT
- 27 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2013 New trial record